A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.
- Citation:
- Future Oncol 1-25
- Year:
- 2024
- Type:
- Manuscript
- Funding:
- AFT
- Endpoint:
- No-Endpoint
- Analysis:
- Other
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None